SUMMARY In vitro studies were performed to investigate the direct effects of the cyclooxygenase inhibitors (COI), meclofenamate, imidazol, acetylsalicylic acid (ASA), indomethacin, and acetominophen on the plasma kailikrein system and on urinary kailikrein excretion. Biological (guinea pig ileum) and colorimetric (synthetic substrate) methods were used. Results showed that all COIs except ASA affected both the activation of pre-kallikrein in plasma and the direct activity of plasma kailikrein, but none of the COIs tested was able to alter the urinary kailikrein excretion. Additionally, in Wistar rats we studied the effects of chronic administration of ASA, meclofenamate, and indomethacin on the plasma kailikrein system and urinary kailikrein excretion. In contrast to the in vitro studies, administration of these COIs reduced the amount of total 24-hour urinary kailikrein excretion. Moreover, the pre-plasma kailikrein and total plasma kailikrein levels were diminished in all experimental groups. However, only ASA and meclofenamate increased the free-plasma kailikrein levels despite the fact the three COIs used reduced the high molecular weight kininogen. Thus, in vitro data suggest an important and direct effect of meclofenamate, imidazol, indomethacin, and acetominophen on the plasma kailikrein system, without any effect on urinary secretion. ASA was the only COI that showed no direct effect in these experiments. Chronic COI administration in Wistar rats suggests that ASA, meclofenamate, and indomethacin affect both the plasma kallikrein-kinin system and kailikrein excretion. When these drugs are used to evaluate the interactions between prostaglandins and the kallikrein-kinin system, their possible effects through both mechanisms, directly or via prostaglandin inhibition, should be considered. the circulation to the kidney was sustained by a major prostaglandin component; withdrawal of this component resulted in significant hemodynamic effects, particularly reduction in blood flow.
S INCE the observation by Vane
1 that aspirin-like drugs inhibit prostaglandin biosynthesis, the effects of the prostaglandin system on renal function have been investigated. Evidence has supported the concept that the actions of aspirin-like drugs are mediated by inhibition of the cyclooxygenase enzyme. 2 This inhibition reduces or abolishes the formation of endoperoxides and their subsequent products. 3 In studies of prostaglandin inhibition it was possible to observe that, when renal function was compromised, the circulation to the kidney was sustained by a major prostaglandin component; withdrawal of this component resulted in significant hemodynamic effects, particularly reduction in blood flow. 45 Prostaglandins (PGs) modulate the effects of vasoactive hormones by attenuating the renal actions of the renin-angiotensin system 6 and contributing to or mediating their effects on the kallikrein-kinin system (KKS). 7 Moreover, renal KKS is able to stimulate the renal prostaglandin system. 7 Evidence that the renal KKS and PGs are interrelated comes from the relationships between the urinary excretion rates of kailikrein and PGs, 8 the effect of alterations in KKS activity on renal PGs production, 9 ' I0 and the effect of PGs" or cyclooxygenase inhibitors (COIs) on the renal KKS. 12 Therefore, we decided to evaluate if COIs, per se, can affect the KKS directly, since many studies analyzed the interaction between both systems by employing prostaglandin inhibition only.
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Methods
In Vitro Studies
To study the in vitro effects of COIs on plasma kallikrein (PK) and urinary kallikrein (UK), meclofenamate (Ache" Laboratories, Sao Paulo, Brazil); imidazole (Sigma Chemical Company, St. Louis, Missouri), acetylsalicylic-acid (ASA, Smith Kleine-Enila Laboratories, Rio de Janeiro, Brazil), indomethacin (Merck Sharp and Dohme, Sao Paulo, Brazil), and acetominophen (Winthrop Products, Inc., Sao Paulo, Brazil) were used at a final concentration of 4 mg/ml sample. Urine and plasma were obtained from a pool of normal Wistar rats. We employed both biological and colorimetric methods.
Biological Method
The activation of pre-PK to PK was evaluated using plasma samples diluted threefold in 0.9% NaCl with 2N HC1 in order to obtain and maintain a pH 2.0 at room temperature. After 15 minutes, a solution of 2N NaOH was added until pH 7.4 was achieved; this incubate was maintained for 3 hours at 37° C, and the reaction was interrupted in an ice bath. The endproduct was measured against bradykinin (Protein Research Foundation, Tokyo, Japan) as standard, in guinea pig ileum.
COIs were added before or after plasma acidification, to determine the effects on activation (pre-PK to PK) or in the activity, respectively. The UK activity was evaluated using 0.5 ml of cooled rat urine, incubated with COI to a final volume of 1 ml in 0.05 M Tris HC1 buffer at pH 8.0. These samples were maintained for 10 minutes at room temperature. The UK activity was measured by the direct method of Prado and colleagues' 3 using rat plasma kininogen as substrate and lysil-bradykinin (Protein Research Foundation, Tokyo, Japan) as standard.
Colorimetric Method
The activation of pre-PK and the activity of free-PK were measured using H-D-Pro-Phe-Arg-paranitroanilide (PPA-pNa, Kabi Diagnostic, Stockholm, Sweden), a synthetic substrate. To determine if COI inhibited the PK activation, the drugs were added before the pre-PK activation with dextran sulfate (6.67 /xg/ml plasma, Sigma Chemical Company, St. Louis, Missouri) for 2 minutes at room temperature. Then, 10 /xl of activated plasma was incubated with 122 /u,mol of synthetic substrate in 0.05 M Tris HC1 pH 8.0 buffer to a final volume of 1.0 ml, for 5 minutes (37° C). The reaction was interrupted with the addition of 0.1 ml 50% acetic acid. The endproduct (paranitroaniline, pNa) was read at 405 nm in a spectrophotometer (Coleman Junior II). The free-PK activity was evaluated incubating COI with 30 (i\ of plasma in a final volume of 90 IM\ in buffer solution (0.05 M Tris HC1, pH 8.0). After 10 minutes at room temperature, 30 /AI was incubated with PPA-pNa for 20 minutes (37° C); the reaction was interrupted and the endproduct measured under the same conditions as above. Urinary kallikrein activity was evaluated in a 20 pil urine sample in which COIs were incubated. A final volume of 0.97 ml was obtained with buffer solution (0.05 M Tris HC1, pH 8.0). After 10 minutes at room temperature, 129 /xmol of H-D-Val-Leu-Arg-paranitroanilide (VLA-pNa, Kabi Diagnostica, Stockholm, Sweden) was added and maintained for 5 minutes (37° C). The reaction was interrupted, and the endproduct was measured under the same condidtions described for activation of pre-PK.
In Vivo Studies
Rats weighing 300 to 350 g were kept in metabolic cages for 12 days. After the third day, COI injections were initiated and maintained daily for 9 days. Urine collections were made every 24 hours starting on the third caging day; during this period the animals were maintained without food but with free water access. The drugs used (i.p.) were indomethacin (2 mg/kg/ day, n = 9); ASA (10 mg/kg/day, n = 9) and meclofenamate (2 mg/kg/day, n = 9). The control group (n = 9) received 0.1 ml of 0.9% NaCl i.p. per day.
Urine from Days 1 , 3 , 5 , 7 , and 9 were analyzed for UK by the colorimetric method described above. After 9 days of treatment, the plasma samples were withdrawn for KKS estimation. The pre-PK was calculated by the difference between total-PK (activated PK plus free-PK) and free-PK (colorimetric method). Also, total plasma kininogen, high molecular weight (HMW), and low (LMW) kininogen were measured. The total plasma and HMW kininogen levels were determined as described by Prado et al. ' 3 with rat urinary kallikrein and rat plasma kallikrein respectively. LMW kininogen was obtained by the difference between total plasma kininogen and HMW kininogen levels.
Statistical Analysis
Paired and unpaired Student's t tests were used when appropriate. Statistical significance was defined as p < 0.05. Results are expressed as means ± SE.
Results
In Vitro Studies Table 1 shows that imidazbl, indomethacin, and acetominophen inhibited (by biological method) 20%, 23%, and 70% of the pre-PK activation when compared with control, respectively. Additionally (by colorimetric method) we observed that meclofenamate inhibited 13% of the pre-PK activation. Meclofenamate and imidazol inhibited (by biological method) the PK activity in 45% and 30%, respectively, and acetominophen inhibited 13% by colorimetric method (table  1) . In contrast, none of COIs studied were able to inhibit the UK activity, both by colorimetric or biological testing methods. To evaluate the relationship between both biological and colorimetric methods, we incubated different concentrations of rat UK and PK with an excess of synthetic or natural (rat plasma) substrates. Tables 2 and 3 show a proportional correlation in both curves only with low concentrations of rat UK and PK. At higher concentrations in the excess Values are means ± SEM. M = meclofenamate; 1m = imidazol; ASA = acetylsalicylic acid; I = indomethacin; Ac = acetominophen.
*p < 0.05 vs control. substrate, both methods were not well correlated. Therefore, the differences between both methods observed in table 1 were dueto an unproportional correlation in the concentrations of enzymes used.
In Vivo Studies
As shown in table 4, ASA decreased UK excretion after the 3rd day (C = 1785 ± 125; ASA = 800 ± 85 pmol pNa;p < 0.005) until the 9th day (C = 1374 ± 138, ASA = 879 ± 156 pmol pNa;p < 0.025) when compared with the control (C) group. Meclofenamate decreased the UK excretion after the 3rd day (C = 1785 ± 125; M = 1437 ± 126 pmol pNa,/? < 0.05), but the excretion rate returned to control levels after the5thday(C = 1604 ± 179;M = 1348 ± 154pmol pNa, p > 0.05). Indomethacin decreased UK excretion after the 7th day (C = 1177 ± 139; I = 739 ± 116 pmol pNa, p < 0.025), and this became much more accentuated after the 9th day (C = 1374 ± 138; I = 461 ± 108 pmol pNa, p < 0.001).
The plasma parameters measured show that, in contrast to indomethacin (76 ± 8 pmol pNa/ml/min), ASA (172 ± 11 pmol pNa/ml/min, p < 0.001) and meclofenamate (256 ± 10 pmol pNa/ml/min, p < 0.001) increased the levels of free PK when compared with the control group (65 ± 7 pmol pNa/ml/min) (table 5). These increases were significantly higher for meclofenamate (256 ± 10 pmol pNa/ml/min) than for ASA (172 ± 11 pmol pNa/ml/min, p < 0.001 vs meclofenamate). Since the total PK was significantly decreased with ASA (380 ± 15 pmol pNa/ml/min), meclofenamate (344 ± 9 pmol pNa/ml/min), and indomethacin (352 ± 18 pmol pNa/ml/min), compared with the control group (456 ± 14 pmol pNa/ml/min, p < 0.001), the levels of pre-PK were also diminished for all COIs tested; and the lowest value observed was for meclofenamate (M = 9 9 ± 1 2 , C = 3 9 1 ± 1 1 pmol pNa/ml/min, p < 0.001) (table 5) . In contrast to ASA (3.05 ± 0.15 nmol kinin/ml plasma,/? > 0.05), meclofenamate decreased (2.66 ± 0.15 nmol kinin/ml plasma, p < 0.005) and indomethacin increased (5.29 ± 0.24 nmol kinin/ml plasma, p < 0.001) the levels of total PKgn (table 6) when compared with control (3.36 ± 0.12 nmol kinin/ml plasma). The levels of HMW kininogen were diminished for all COIs (ASA = 1.05 ± 0.03, p -C0.00I; meclofenamate = 1.29 ± 0.09, p < 0.005; and indomethacin = 1.02 ± 0.07 nmol kinin/ml plasma, p< 0.001) compared with control values (1.63 ± 0.03 nmol kinin/ml plasma). When we analyzed the levels of LMW kininogen, we observed that ASA (2.00 ± 0.16 nmol kinin/ml plasma) and meclofenamate (1.39 ± 0.21 nmol kiniri/ml plasma) did not alter them significantly but indomethacin did (4.27 ± 0.24 nmol kinin/ ml plasma, p < 0.001) compared with controls (1.72 ± 0 . 1 1 nmol kinin/ml plasma).
Discussion
Since COIs are blockers of the prostaglandin system, they art useful drugs with which to study interactions between the prostaglandin and kallikrein-kinin systems. 7 Therefore, we decided to test whether COIs have a direct effect on the kaj)ikrein-kinin system, by employing an in vitro protocol. We observed that imidazol, indomethacin, and acetominophen were able to inhibit the activation of pre-PK to PK, by both biological and colorimetric methods. With meclofenamate, however, only the colorimetric method achieved inhibition of the activation.
As shown in table 1, we observed qualitative and quantitative differences between both methods. The dose-response curves (tables 2 and 3) in experiments using an excess of the enzyme and substrate showed that both the biological and colorimetric methods were unable to obtain a correlation at the highest concentrations. The acid activation in the biological method and the surface activation in the colorimetric method could probably account for the different interactions between . the COIs and pre-enzyme. 14 The activity of PK was also affected by meclofenamate, imidazol, and acetominophen. Therefore, all but ASA affected the plasma kallikrein system directly, while none affected the urinary kallikrein activity.
To evaluate the actions of ASA, meclofenamate, and indomethacin on the kallikrein-kinin system in vivo, rats were chronically treated with these inhibitors in doses that blocked protaglandin biosynthesis.
15 ' 6 In contrast to the in vitro studies, chronic administration of ASA, meclofenamate, and indomethacin altered the total UK excretion. A decline in UK was caused by ASA on Days 3, 5, and 9 of treatment, by meclofenamate only on Day 3, and by indomethacin on Days 7 and 9. Therefore, all COIs tested reduced the UK excretion, with small differences in the day of the greatest action. These declines were probably due to an effect on prostaglandin inhibition and therefore on UK 7 since the doses of COI used had previously demonstrated an ability to decrease urinary prostaglandin excretion. 15 - 16 However, we cannot exclude the possibility that these drugs of some of their metabolites cause a direct effect on UK excretion and/or activity. Moreover, a striking effect on the plasma kallikrein-kinin system was observed. The pre-PK and total-PK levels were diminished in all groups when compared with control. ASA probably affected the synthesis of pre-PK, since no interference in the PK activation or activity was observed in in vitro studies. With meclofenamate and indomethacin, however, we cannot conclude if their effects are due to an in'vivo action, since both drugs also caused effects during in vitro studies. Additionally, due to an impressive increase in free-PK with ASA and meclofenamate, a decline in HMW kininogeh was observed. l7 A greater effect was observed with meclofenamate (p < 0.025) since there was a much higher value for free-PK. For all drugs tested but indomethacin, we observed an increase in total plasma kininogen and, therefore, an increase in LMW kininogen that blunted the decline of HMW kininogen. The increase in LMW kininogen was probably due to a decrease in consumption, since we observed an important decline in UK on Day 7, an enzyme that hydrolyzes the LMW kininogen. without any effect on UK activity. The in vivo data, on the other hand, suggest that ASA, meclofenamate, and indomethacin. alter both UK excretion and the plasma kallikrein-kinin system.
The observation that COIs have direct action on the kalllikrein-kinin system implies that previous work analyzing the interaction between prostaglandins arid the kallikrein-kinin system have to be reevaluated, since many of these investigators assumed that COIs act only on the prostaglandin system. Interactions between both systems will be better delineated when the new generation of specific blockers of prostaglandins and the kaJlikrein-kinin system are developed.
